Systemic, pulmonary, and renal hemodynamic effects of endothelin ET(A/B)-receptor blockade in patients with maintained left ventricular function

Journal of Cardiovascular Pharmacology

Volumn 36, Issue 3, 2000, Pages 302-309

  Fleisch, Martin ^a   Sütsch, Gabor ^b   Yan, Xiao Wei ^b   Wenzel, René R ^a   Binggeli, Christian ^b   Bianchetti, Mario G ^c   Meier, Bernhard ^a   Kiowski, Wolfgang ^b   Lüscher, Thomas F ^b  

^a BERN UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c UNIVERSITY OF BERN   (Switzerland)

Author keywords

Endothelin antagonism; Hemodynamics; Renal function; Vascular resistance

Indexed keywords

ACETYLSALICYLIC ACID; AMILORIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CHLORTALIDONE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; ENDOTHELIN RECEPTOR ANTAGONIST; FUROSEMIDE; HYDROCHLOROTHIAZIDE; MIANSERIN; NITRATE; OMEPRAZOLE; SIMVASTATIN; TAK 044; WARFARIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; FEMALE; HEART INDEX; HEART LEFT VENTRICLE FUNCTION; HEART RATE; HUMAN; KIDNEY BLOOD FLOW; KIDNEY FUNCTION; LUNG ARTERY PRESSURE; LUNG CAPILLARY PRESSURE; LUNG HEMODYNAMICS; MALE; MEAN ARTERIAL PRESSURE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECEPTOR BLOCKING; SYSTEMIC VASCULAR RESISTANCE; VASODILATATION;

EID: 0033840398     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-200009000-00004     Document Type: Article

References (41)

1. The endothelium in coronary vascular control
2. Endothelin-1-induced vasoconstriction in humans: Reversal by calcium channel blockade but not by nitrovasodilators or endothelium-derived relaxing factor
3. Endothelins come of age
4. A novel potent vasoconstrictor peptide produced by vascular endothelial cells
5. Angiotensin II increases tissue endothelin and induces vascular hypertrophy in vivo: Reversal by ET(A)-receptor antagonist
6. Endothelin-1 is involved in norepinephrine-induced ventricular hypertrophy in vivo: Acute effects of bosentan, an orally active, mixed endothelin ET(A) and ET(B) receptor antagonist
7. Oxidized low density lipoproteins induce mRNA expression and release of endothelin from human and porcine endothelium
8. Angiotensin II increases vascular and renal endothelin-1 and functional endothelin converting enzyme activity in vivo: Role of ET(A) receptors for endothelin regulation
9. The endothelin ET(B) receptor mediates both vasodilation and vasoconstriction in vivo
10. Both ET(A) and ET(B) receptors mediate contraction to endothelin-1 in human blood vessels
11. Contribution of endogenous generation of endothelin-1 to basal vascular tone
12. Formation by the endothelium of prostacyclin, nitric oxide and endothelin
13. Endothelin stimulated by angiotensin II augments contractility of spontaneously hypertensive rat resistance arteries
14. 13 receptors in rats
15. Human pulmonary circulation is an important site for both clearance and production of endothelin-1
16. Endothelin receptor antagonists inhibit endothelin in human skin microcirculation
17. Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist
18. Pharmacology of a nonselective ET(A) and ET(B) receptor antagonist, TAK-044 and the inhibition of myocardial infarct size in rats
19. The endothelin system in cardiovascular disease
20. Endothelin-1 in pulmonary hypertension associated with high-altitude exposure
21. Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure
22. Systemic endothelin receptor blockade decreases peripheral vascular resistance and blood pressure in humans
23. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension
24. Increased plasma endothelin-1 in pulmonary hypertension: Marker or mediator of disease?
25. Effects of endothelin-1 on renal function in humans: Implications for physiology and pathophysiology
26. Radioimmunoassay of endothelin in human plasma
27. A new endothelin receptor antagonist, TAK-044, shows long-lasting inhibition of both ET(A)-and ET(B)-mediated blood pressure responses in rats
28. Cyclic hexapeptide endothelin receptor antagonist highly potent for both receptor subtypes ET(A) and ET(B)
29. Age and hypertension differently affect coronary contractions to endothelin-1, serotonin, and angiotensins
30. Anatomic heterogeneity of vascular aging: Role of nitric oxide and endothelin
31. Short-term effect of an orally active endothelin-receptor antagonist in patients with severe chronic heart failure
32. Acute and short-term effects of the nonpeptide endothelin-1 receptor antagonist bosentan in humans
33. Vasodilator effects of endothelin-converting enzyme inhibition and endothelin ET(A) receptor blockade in chronic heart failure patients treated with ACE inhibitors
34. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension
35. Clinical aspects of sympathetic activation and parasympathetic withdrawal in heart failure
36. Acute hemodynamic and neurohumoral effects of selective ETA receptor blockade in patients with congestive heart failure
37. Endothelin antagonists on the clinical horizon in nephrology
38. Role of physical factors in the acute changes in renal function elicited by antihypertensive drugs
39. Acute effects of captopril on renal function in hypertensive patients
40. Effect of different endothelin receptor antagonists and of the novel non-peptide antagonist Ro 46-2005 on endothelin levels in rat plasma